SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-057719
Filing Date
2020-12-18
Accepted
2020-12-18 17:17:28
Documents
12
Period of Report
2020-12-14
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K WATERTOWN LEASE TERMINATION ljpc-8k_20201214.htm   iXBRL 8-K 31321
  Complete submission text file 0001564590-20-057719.txt   160164

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ljpc-20201214.xsd EX-101.SCH 5828
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ljpc-20201214_lab.xml EX-101.LAB 19478
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ljpc-20201214_pre.xml EX-101.PRE 11669
5 EXTRACTED XBRL INSTANCE DOCUMENT ljpc-8k_20201214_htm.xml XML 3565
Mailing Address 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121
Business Address 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121 858-207-4264
LA JOLLA PHARMACEUTICAL CO (Filer) CIK: 0000920465 (see all company filings)

IRS No.: 330361285 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36282 | Film No.: 201401523
SIC: 2836 Biological Products, (No Diagnostic Substances)